A major shift in the pharmaceutical world – the patent behind Ozempic’s key ingredient has expired across major markets, opening the floodgates for cheaper, mass-produced versions of the blockbuster drug. Andrea Heng and Hairianto Diman explore how countries like India and China are already gearing up to roll out low-cost generics at scale, potentially slashing prices by more than half and expanding access to millions and what this means for the future of weight-loss and diabetes treatment. To find out more, they speak with Evan Seigerman, Head of Healthcare Research focusing on BioPharma and Biotechnology, BMO Capital Markets.

A major shift in the pharmaceutical world &ndash; the patent behind Ozempic&rsquo;s key ingredient has expired across major markets, opening the floodgates for cheaper, mass-produced versions of the blockbuster drug. Andrea Heng and Hairianto Diman explore how countries like India and China are already gearing up to roll out low-cost generics at scale, potentially slashing prices by more than half and expanding access to millions and what this means for the future of weight-loss and diabetes treatment. To find out more, they speak with Evan Seigerman, Head of Healthcare Research focusing on BioPharma and Biotechnology, BMO Capital Markets.

The best interviews from CNA938 on Singapore news, current affairs, health, entertainment and money.

The best interviews from CNA938 on Singapore news, current affairs, health, entertainment and money.

CNA938 Rewind

The best interviews from CNA938 on Singapore news, business updates, entertainment and food.

The best interviews from CNA938 on Singapore news, business updates, entertainment and food.